RTW Investments’s Achilles Therapeutics ACHL Stock Holding History

RTW Investments’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,229	Closed	-$61K	–	122
2021 Q4	$61K	Buy	+12,229	New	+$74K	﹤0.01%	123

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

RTW Investments's ACHL Position: Q1 2022 in Review

RTW Investments sold out of Achilles Therapeutics (ACHL) in Q1 2022, closing a stake of 12,229 shares — an estimated $61K sold.

RTW Investments first reported a position in ACHL in Q4 2021 and held it in 1 quarter. The position peaked at $61K in Q4 2021. 25 funds tracked by Wall St. Rank hold ACHL as of Q1 2022.

RTW Investments reported no remaining Achilles Therapeutics position as of Q1 2022 after selling out during the quarter.
RTW Investments sold 12,229 Achilles Therapeutics shares in Q1 2022, an estimated $61K.
RTW Investments first reported a position in Achilles Therapeutics in Q4 2021 and held it in 1 quarter.
RTW Investments's Achilles Therapeutics position peaked at $61K in Q4 2021.
25 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2022.

Based on RTW Investments's 13F filing for Q1 2022, filed 16 May 2022.